Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.

Abstract

The review focuses on recent aspects (last three years) of glycosylation analyses that provide relevant information about cancer. It includes recent development in glycan and protein enrichment methods for discovery of cancer markers. It will however focus on the recent technological developments in mass spectrometry (MS), bioinformatics and separation methods as they apply toward identifying cancer markers. More specifically, it will cover advances in matrix-assisted laser desorption/ionization (MALDI), electrospray ionization (ESI), capillary electrophoresis (CE), and liquid chromatography (LC) coupled to mass spectrometry. The discussions will include glycans, recently identified as potential markers for cancer that have been discovered using the highlighted technologies. We will also discuss emerging glycoproteomic techniques and site-specific methods, and how these methods are being utilized for cancer biomarker discovery. The large amount of data and the complexity of glycoproteomic analysis have been the impetus for developing bioinformatic methods for assigning glycosylation sites and characterizing the potentially very large site- or microheterogeneity. This review will cover the most recent advancements in biomarker discovery of N- and O-glycosylation of proteins as well as the glycolipids. This group collectively constitutes glycosylation on the cell membrane or the glycocalyx. The review will also highlight methods that are highly reproducible, with low coefficient of variation (CV), and scalable for large sample sets. The reader is also referred to other notable earlier reviews on glycomic biomarkers for cancer. Mereiter et al. describe the recent glycomic effort in gastrointestinal cancer.1 A review focused on N-glycomic analysis of colorectal cancer has been published by Sethi and Fanayan.2 N-Glycan, O-glycan, and glycolipid characteristics of colorectal cancer were reviewed by Holst et al.3 Muchena et al. have provided a more general review of glycan biomarkers covering up to the current review period.4 The field of glycoscience also covers a broad area of structures and may include highly anionic (glycosaminoglycans) and monosaccharide (e.g. O-GlcNAc) modifications that require their specific and unique sets of analytical tools. The latter topics are not covered in this review. 1.1. Background of Glycosylation and Cancer There is nearly 50 years of research illustrating that changes in glycosylation accompany cancer.5 Glycosylation is a dynamic process intimately involved in key processes in cells, including cell-cell and cell-extracellular communication as well as cell-cell adhesion, and cellular metabolism. Glycans expressed in several types of glycoconjugates are known to change during cancer genesis and progression.6 These changes increase the structural heterogeneity and alter the functions of cells.7 Glycosylation has been found to enable tumor-induced immunomodulation and metastasis.8–10 The cell-surface structures allow the immune cells to differentiate self/normal cells from non-self/abnormal cells.11 For example, terminal residues on N-glycans, such as sialic acids, are involved in immunity and cell-cell communication.12 Changes in glycosylation of adhesion proteins can largely influence their binding properties, leading to altered cell-cell or cell-matrix contacts.13 Other types of glycans are also involved in cancer. Gangliosides and sphingolipids are involved in transmembrane communication vital in tumor cell growth and invasion.14 Glycosaminoglycans are involved in tumor cell migration15 and motility.16–18 The search for effective markers is aided by the understanding of how glycans are synthesized. The glycan biosynthetic process is a non-template process involving multiple enzymes, some performing competing activities. It is estimated that more than 300 metabolic enzymes, composed of glycosyltransferases and glycosidases, are involved in the biosynthesis and processing of glycans.19–20 The best-known series of pathways belongs to the production of N-glycans (Figure 1). They illustrate the large degree of structural heterogeneity in glycosylation. N-Glycans are produced in a step-wise process beginning with the production of high mannose structures on a lipid, which are transferred to the nascent polypeptide chain to guide protein folding. Once folded, the glycans are then trimmed back and extended to form complex and hybrid structures. The folded protein can be secreted with glycans that range from early in the process to yield high mannose structures to later in the process corresponding to complex or hybrid structures. The number of structures for one glycosylation site can vary by a large degree, from a handful for transferrin21 to over 70 structures for IgG, the most abundant serum glycoprotein.22–23 Open in a separate window Figure 1. Representation of the glycosylation pathway of proteins. The pathway illustrates the complexity and heterogeneity of structures. The proteins may exit the pathway with various levels of glycosylation.